MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.820
+0.170
+4.66%
After Hours: 3.820 0 0.00% 16:35 05/17 EDT
OPEN
3.660
PREV CLOSE
3.650
HIGH
3.830
LOW
3.550
VOLUME
220.04K
TURNOVER
--
52 WEEK HIGH
12.15
52 WEEK LOW
3.500
MARKET CAP
121.25M
P/E (TTM)
-2.3197
1D
5D
1M
3M
1Y
5Y
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and entertainment company as analysts pointed to benefits from the reopening of theme parks...
Benzinga · 18h ago
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first operating loss as a listed company, as a record regulatory fine it was
Benzinga · 3d ago
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the stock reversed the earnings-driven gains of the previous session.
Benzinga · 4d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 5d ago
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics company reported strong earnings on Tuesday.
Benzinga · 5d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 6d ago
Global Stem Cell Market Analysis, Scope and Forecast By 2021 to 2027
May 10, 2021 (Market Insight Reports) -- Selbyville, Delaware Stem Cell Market research is an intelligence report with meticulous efforts undertaken to study...
Market Insight Reports · 05/10 10:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTI stock price target is 9.08 with a high estimate of 12.50 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 5.95M
% Owned: 18.76%
Shares Outstanding: 31.74M
TypeInstitutionsShares
Increased
6
89.61K
New
14
866.88K
Decreased
10
384.84K
Sold Out
2
350
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Lead Director/Independent Director
Doron Shorrer
Director
Rami Levy
Director
Maital Shemesh-Rasmussen
Independent Director
Isaac Braun
Independent Director
Issac Braun
Independent Director
Mark Germain
Independent Director
Moria Kwiat
No Data
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.